Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...

Eli Lilly partnership aims to identify new treatments for ALS based on antibodies from people with very slow disease ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...

targeting calpain-2 for people living with amyotrophic lateral sclerosis (ALS). With the clinical hold lifted, Amylyx is now working to open U.S. sites for screening, enrollment, and dosing.

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease ... ALS has a significant impact due to its fatal nature and lack of a definitive cure. The ALS treatment market is expected to ...

The ALS Association will host its second ALS Nexus conference in August, with the goal of making the disease a livable one ...

For the primary analysis, 186 participants who were randomized to receive DNL343 treatment were compared to 139 participants randomized to receive placebo in this regimen (n=63) or shared from a ...

Ractigen Therapeutics has dosed the first subject in the randomised Phase I clinical trial of its small interfering RNA (siRNA) therapy, RAG-17, for treating amyotrophic lateral sclerosis (ALS ...

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of amyotrophic lateral ...

(MENAFN- EIN Presswire) What contributions are AB Science, Alector, GSK, and others making to the Amyotrophic Lateral Sclerosis treatment market? LAS VEGAS , NV, UNITED STATES, December 16 ...